Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection
Author(s)Archary, Derseree; Rong, Rong; Gordon, Michelle L.; Boliar, Saikat; Madiga, Maphuti; Gray, Elin S.; Dugast, Anne-Sophie; Hermanus, Tandile; Goulder, Philip J. R.; Coovadia, Hoosen M.; Werner, Lise; Morris, Lynn; Alter, Galit; Derdeyn, Cynthia A.; Ndung'u, Thumbi; ... Show more Show less
MetadataShow full item record
Neutralizing (nAbs) and high affinity binding antibodies may be critical for an efficacious HIV-1 vaccine. We characterized virus-specific nAbs and binding antibody responses over 21 months in eight HIV-1 subtype C chronically infected individuals with heterogeneous rates of disease progression. Autologous nAb titers of study exit plasma against study entry viruses were significantly higher than contemporaneous responses at study entry (p=0.002) and exit (p=0.01). NAb breadth and potencies against subtype C viruses were significantly higher than for subtype A (p=0.03 and p=0.01) or B viruses (p=0.03; p=0.05) respectively. Gp41-IgG binding affinity was higher than gp120-IgG (p=0.0002). IgG–FcγR1 affinity was significantly higher than FcγRIIIa (p<0.005) at study entry and FcγRIIb (p<0.05) or FcγRIIIa (p<0.005) at study exit. Evolving IgG binding suggests alteration of immune function mediated by binding antibodies. Evolution of nAbs was a potential marker of HIV-1 disease progression.
DepartmentMassachusetts Institute of Technology. Department of Biological Engineering; Ragon Institute of MGH, MIT and Harvard
Archary, Derseree, Rong Rong, Michelle L. Gordon, Saikat Boliar, Maphuti Madiga, Elin S. Gray, Anne-Sophie Dugast, et al. “Characterization of Anti-HIV-1 Neutralizing and Binding Antibodies in Chronic HIV-1 Subtype C Infection.” Virology 433, no. 2 (November 2012): 410–420. © 2012 Elsevier Inc.
Final published version